Engflag

Duplicam

Quick links to important sections

Duplicam

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duplicam

Property Description
Active ingredient Meloxicam
Form Tablet, Capsule, Solution for Injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Alleviates pain, swelling, and fever
Origin Synthetic compound

The Core Identity of Duplicam: NSAID Classification and Origin

Duplicam is a pharmaceutical product with systemic action whose primary function is to act against the processes of pain and swelling in the body. Its active component, Meloxicam, is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging specifically to the oxicam derivative subgroup. Meloxicam is defined as a synthetic compound with a unique chemical structure. This is a single-ingredient product, relying exclusively on Meloxicam for its therapeutic effects. The designation as an NSAID establishes its fundamental identity within the class of anti-inflammatory agents.

Composition and Available Preparations (Meloxicam Basis)

The core composition of Duplicam is its active ingredient, Meloxicam, which is delivered within a necessary pharmaceutical excipient system to ensure effective absorption and distribution. Duplicam is made available in several distinct dosage forms for patient use, commonly including the tablet and capsule for oral intake, as well as a sterile solution for injection for parenteral administration. This variety of preparations ensures the drug can be introduced into the body effectively to achieve comprehensive systemic action. Clinical pharmacology data confirms the substance is characterized by a long half-life, a key differentiating factor that supports a sustained anti-inflammatory and pain-relieving effect over an extended period.

General Purpose: Targeting Pain, Swelling, and Fever

The general purpose of Duplicam is to provide relief from discomfort by addressing the three cardinal symptoms associated with the inflammatory response. The medication is functionally categorized as an analgesic (pain-relieving), an anti-inflammatory (swelling-reducing), and an antipyretic (fever-reducing) agent. Its effects stem from its established mechanism, which involves the inhibition of prostaglandin synthesis, thereby interrupting the molecular signaling pathways responsible for triggering these symptoms. Consequently, Duplicam is clinically recognized for its ability to systematically modulate the body’s reaction, serving as a powerful agent for reducing pain, suppressing inflammation, and lowering elevated temperatures, making it a typical agent for conditions involving chronic discomfort.

What side effects are possible with Duplicam?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse reactions and high-level safety patterns of Duplicam (Meloxicam), as classified by government regulatory authorities in official prescribing documents.

Documented Adverse Reactions

Side effects are categorized by frequency based on clinical data, as defined in regulatory standards:

  • Common Reactions (affecting up to 1 in 10 people): Primarily involve the Gastrointestinal System, including dyspepsia, nausea, abdominal pain, diarrhea, and constipation. Headache and general edema (fluid retention) are also classified as common.
  • Uncommon Reactions (affecting up to 1 in 100 people): Include dizziness, anemia, vertigo, and various skin reactions like rash and pruritus.
  • Rare Reactions (affecting up to 1 in 1,000 people): Involve vision disturbances, tinnitus (ringing in the ears), and serious inflammatory conditions such as gastroduodenal ulceration.

Serious Safety Risks

Regulatory warnings highlight risks of serious adverse reactions that impact major organ systems:

  1. Gastrointestinal Risk: The potential for serious events, including bleeding, ulceration, or perforation of the stomach or intestines, is documented. This risk is observed to be more frequent during the early stages of treatment and increases with duration of use.
  2. Cardiovascular Risk: An increased risk of serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke, is associated with the medication. This risk may occur early in treatment.

Population and Usage Restrictions

Safety labeling includes specific constraints:

  • The medicine is contraindicated in individuals with a history of asthma or allergic reactions to aspirin or other NSAIDs, as well as those with severe, uncontrolled heart failure or active gastrointestinal bleeding.
  • Older adults are noted to have a greater risk for serious gastrointestinal and renal adverse events. Use during the third trimester of pregnancy is contraindicated.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Duplicam (Meloxicam) as potentially leading to severe systemic effects. Initial documented manifestations commonly include gastrointestinal symptoms such as nausea, vomiting, and epigastric pain, alongside central nervous system effects like lethargy or drowsiness. More serious intoxication can present with signs of severe gastrointestinal bleeding, convulsions, or respiratory depression. Documented life-threatening outcomes include acute renal failure, hepatic dysfunction, and cardiovascular collapse.

Required Emergency Actions

Management of Meloxicam overdose is strictly symptomatic and supportive, as regulatory documents confirm no specific antidote is known. This necessitates professional medical intervention. Regulatory guidance mandates seeking immediate medical attention if an overdose is suspected. Urgent contact with emergency services is required if the individual collapses, experiences a seizure, has trouble breathing, or exhibits signs of severe systemic toxicity.

Official labeling describes procedural steps such as gastric lavage, followed by the administration of activated charcoal or Cholestyramine, to reduce systemic absorption in the acute setting. It is also documented that elderly patients face an elevated risk for serious gastrointestinal adverse events in the context of overdose.

Therapeutic Uses of Duplicam

What Duplicam Treats: Main Uses and Benefits

The primary use of Duplicam (Meloxicam) is to provide symptomatic support for conditions characterized by symptoms related to physical discomfort and heightened physiological activity. The medication is generally used to help relieve symptoms like pain, tenderness, swelling, and stiffness. It is commonly used to manage conditions presenting with acute episodes and chronic inflammatory diseases, particularly Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS).

It is applied in clinical settings that involve acute or unstable symptom patterns, such as flare-ups of chronic pain or post-operative discomfort. The application is relevant when supportive symptom management is appropriate:

“It supports patients during difficult episodes by easing distress and assists with maintaining functional stability.”

This medication is applied in addressing symptom clusters that may become intense or disruptive, and generally provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Joint and Musculoskeletal Pain

Duplicam is relevant for easing symptoms that create noticeable physiological strain arising from conditions involving inflammatory or irritative states and articular stiffness.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Duplicam? — Official Regulatory Information

Official regulatory documents establish strict eligibility and non-eligibility criteria for using this medicine.

Eligibility Status Populations / Conditions
Absolutely Contraindicated (Must Not Be Used) Known hypersensitivity to the drug or any component, or a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy at about 30 weeks gestation and later.
Use Restricted/Avoided Patients with severe renal impairment (unless on hemodialysis), advanced renal disease, or severe heart failure.
Patients with active or recent gastrointestinal bleeding, ulceration, or perforation.
Age-Related Rules Generally restricted to adults. Specific formulations are approved for Juvenile Rheumatoid Arthritis in children 2 years of age and older who weigh ge 60 kg (for some tablets).
Pregnancy Status Avoid use at about 30 weeks gestation and later; limit use between about 20 to 30 weeks gestation. Use in nursing mothers should be approached with caution or avoided.

Use of the medicine is allowed for adults and eligible pediatric patients who do not have any of the specified contraindications or limiting conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Duplicam (Meloxicam) as defined in government regulatory labeling. Interaction information is categorized by the regulatory outcome, reflecting pharmacodynamic and pharmacokinetic effects.

Formal Interaction Restrictions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including high-dose salicylates, is officially avoided due to the documented potential for additive gastrointestinal (GI) adverse events. Duplicam is formally contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Documented Interaction Patterns

Interacting Substance or Class Official Interaction Outcome
**Oral Anticoagulants** (e.g., Warfarin), **Antiplatelet Agents**, **SSRIs/SNRIs** Increased risk of bleeding complications (Pharmacodynamic reinforcement).
**Lithium, Methotrexate** Increased plasma concentrations and toxicity risk of the co-administered drug (Reduced renal clearance).
**ACE Inhibitors, ARBs, Diuretics** Diminished antihypertensive/diuretic effect; increased risk of renal function deterioration.
**Alcohol (Ethanol), Tobacco** Increased risk of GI ulceration and bleeding (Additive adverse effects).

Official documents note that the risk of renal function deterioration from co-administration with ACE Inhibitors, ARBs, or Diuretics is heightened in the elderly, volume-depleted, or those with renal impairment. The metabolic pathway of Duplicam involves the CYP2C9 enzyme, and certain inhibitors, like Grapefruit Juice, may increase Meloxicam exposure.

Mechanism of Action

Duplicam's mechanism of action is based on the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This enzyme is predominantly expressed in response to tissue distress, where it mediates the synthesis of key signaling molecules. The drug interferes with the catalytic activity of COX-2, which directly suppresses the prostaglandin synthesis pathway, resulting in a molecular reduction of mediators like Prostaglandin E2 ( PGE2). At the peripheral level, this reduction modulates biochemical pathways involved in nociceptor sensitization and localized tissue fluid accumulation. At the systemic level, the effect modulates the central hypothalamic set point for core body temperature regulation. This coordinated action influences the regulation of core physiological pathways. The mechanism is constrained by its dose-dependent nature; its preferential inhibition of COX-2 weakens at higher concentrations, leading to concurrent inhibition of the constitutive COX-1 isoform.

Dosage and Administration Information

How to Use Duplicam: Official Administration Guidelines

Duplicam (Meloxicam) is administered via the oral route, using tablets, capsules, or suspension, and via the intravenous (IV) route for the injection solution. Specific dosing and schedules are established for standardized use, utilizing the lowest effective dosage for the shortest duration consistent with treatment goals.

Standard Dosing and Frequency

Administration Scope Administration Details
Dosing Schedule (Adults) Oral Tablets/Suspension: Starting dose of 7.5 mg once daily, up to a maximum of 15 mg once daily. Oral Capsules: Starting dose of 5 mg once daily, up to a maximum of 10 mg once daily.
Frequency The total daily dose is administered as a single dose (once daily) for all approved adult and pediatric indications.
Intake Conditions Oral forms may be taken with or without food. Tablets and capsules should be swallowed whole; oral suspension requires gentle shaking before use.

Special Procedural Requirements

Specific administration rules apply to certain populations and methods. The various oral formulations (tablet, capsule, suspension) are not considered interchangeable even at the same milligram strength. For the IV formulation, the 30 mg dose is administered as an IV bolus over 15 seconds, and patients must be well-hydrated prior to the procedure.

Hemodialysis Patients have specific dose restrictions, with the maximum daily dose limited to 7.5 mg for tablets/suspension or 5 mg for capsules. In pediatric use for Juvenile Rheumatoid Arthritis, the dose is calculated by weight, not to exceed 7.5 mg daily. If a dose is missed, it should not be doubled, and the regular once-daily schedule should be resumed.

Recent Clinical Evidence

Duplicam: Overview of Research Evidence

The evidence for Duplicam is derived primarily from short-term, controlled clinical trials across its studied indications. Research focuses on outcomes describing physical discomfort, functional status, and patient-reported changes measured over defined time intervals.

Evidence by Condition

Osteoarthritis (OA): Studies examined patterns of change in outcomes reflecting daily functioning and reduced physical discomfort, largely focusing on the knee and hip joints. Findings describe observed changes measured over periods typically ranging from four weeks to six months.

Rheumatoid Arthritis (RA) & Ankylosing Spondylitis (AS): Research for these conditions, which involve periods of heightened symptoms, explored how specific clinical response criteria and disease activity scores evolved in adult populations during short-term trials. The evidence base contributes to understanding symptom patterns.

Juvenile Idiopathic Arthritis (JIA): Controlled trials for JIA included pediatric patients, with studies exploring short-term symptom changes using specialized American College of Rheumatology pediatric criteria. Findings apply to the specific age groups and disease subtypes that were included in the research.

Uncertainty and Limitations

The research landscape contains acknowledged limitations. Long-term patterns of change are not fully established across all studied populations, as the follow-up durations were often limited. Consequently, information regarding the durability of observed outcomes over many years remains uncertain.

Furthermore, data for certain special populations remain insufficient, and sample sizes were modest in some pediatric trials. A lack of dedicated head-to-head research against all other treatment options is noted, meaning comparative evidence for specific endpoints is limited. The evidence base largely describes what was observed in specific study settings and does not offer individual predictions.

Key Studies & References

  1. Meloxicam (Oral Route) - NIH MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Duplicam (FAQ)

Q: Does it make you sleepy?

A: Official product information, based on clinical studies, indicates that dizziness and somnolence (sleepiness) are very common side effects. This means that these effects were observed in more than 1 in 10 people who took the medication in trials. This potential for CNS effects is an important safety consideration mentioned in regulatory documents.

Q: What are the storage conditions for this medication?

A: According to the official product information in various regions, this medication generally does not require special storage conditions. It is typically recommended to store the medicine at room temperature (e.g., between 15 C and 30 C) in its original packaging. Patients are generally advised to refer to the specific storage information provided on the local product packaging.

Q: Can children 2 years old use it?

A: Regulatory documents indicate that the use of Duplicam depends on the specific condition being treated. For the treatment of partial-onset seizures, the medication is approved for patients 1 month of age and older. However, for other approved indications, such as treating certain types of pain, the medication is typically authorized only for adults or adolescents aged 17 years and older.

Q: Should I avoid alcohol while taking this?

A: Regulatory safety information advises that patients should be counseled about the potential for increased side effects when using alcohol with Duplicam. Since this medicine can cause dizziness and sleepiness, consuming it with alcohol or other medications that affect the Central Nervous System (CNS) may potentially worsen these effects. Official product information suggests that avoiding or significantly limiting alcohol use may be necessary.

How should Duplicam be stored and disposed of?

Storage and Disposal Requirements

Duplicam must be stored according to the requirements set forth in the official regulatory labeling to maintain its stability and effectiveness.

Storage Constraint Official Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Must be protected from excessive heat and moisture. The injection solution requires specific protection from light.
Handling Rules The oral suspension formulation must not be frozen. Liquid containers must be kept tightly closed.
Stability The oral suspension has a defined post-opening discard limit (typically 30 days) that must be strictly followed.

All forms of the medicine must be kept out of the sight and reach of children. Unused or expired Duplicam must be disposed of according to local pharmaceutical waste regulations; it should not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Duplicam found in:

A-Z Index: